- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05921994
Долгосрочное обсервационное, проспективное, многоцентровое исследование для сбора в реальной популяции данных о схеме лечения секукинум-Ат у взрослых пациентов с гнойным гидраденитом средней и тяжелой степени. (ANIMA)
Долгосрочное обсервационное, проспективное, многоцентровое исследование для сбора в реальной популяции данных о схеме лечения секукинум-АТ у взрослых пациентов с умеренным и тяжелым гнойным гидраденитом (HS) (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
-
Aachen, Германия, 52064
- Novartis Investigative Site
-
Ahaus, Германия, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Германия, 09456
- Novartis Investigative Site
-
Bad Steben, Германия, 95138
- Novartis Investigative Site
-
Baden-Baden, Германия, 76530
- Novartis Investigative Site
-
Berlin, Германия, 12159
- Novartis Investigative Site
-
Berlin, Германия, 13595
- Novartis Investigative Site
-
Bielefeld, Германия, 33647
- Novartis Investigative Site
-
Bochum, Германия, 44791
- Novartis Investigative Site
-
Bonn, Германия, 53105
- Novartis Investigative Site
-
Brandenburg, Германия, 14776
- Novartis Investigative Site
-
Bremen, Германия, 28359
- Novartis Investigative Site
-
Buxtehude, Германия, 21614
- Novartis Investigative Site
-
Bückeburg, Германия, 31675
- Novartis Investigative Site
-
Chemnitz, Германия, 09117
- Novartis Investigative Site
-
Chemnitz, Германия, 09113
- Novartis Investigative Site
-
Cologne, Германия, 51065
- Novartis Investigative Site
-
Delitzsch, Германия, 04509
- Novartis Investigative Site
-
Dessau, Германия, 06847
- Novartis Investigative Site
-
Dorsten, Германия, 46282
- Novartis Investigative Site
-
Dortmund, Германия, 44137
- Novartis Investigative Site
-
Dresden, Германия, 01309
- Novartis Investigative Site
-
Düren, Германия, 52349
- Novartis Investigative Site
-
Emsdetten, Германия, 48282
- Novartis Investigative Site
-
Erlangen, Германия, 91054
- Novartis Investigative Site
-
Falkenberg, Германия, 04895
- Novartis Investigative Site
-
Falkensee, Германия, 14612
- Novartis Investigative Site
-
Freising, Германия, 85354
- Novartis Investigative Site
-
Geilenkirchen, Германия, 52511
- Novartis Investigative Site
-
Gera, Германия, 07548
- Novartis Investigative Site
-
Gernsbach, Германия, 76593
- Novartis Investigative Site
-
Gladbeck, Германия, 45964
- Novartis Investigative Site
-
Großenhain, Германия, 01558
- Novartis Investigative Site
-
Hamburg, Германия, 20246
- Novartis Investigative Site
-
Hamburg, Германия, 22143
- Novartis Investigative Site
-
Hanover, Германия, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Германия, 77716
- Novartis Investigative Site
-
Hofgeismar, Германия, 34369
- Novartis Investigative Site
-
Jena, Германия, 07743
- Novartis Investigative Site
-
Jülich, Германия, 52428
- Novartis Investigative Site
-
Karlsruhe, Германия, 76133
- Novartis Investigative Site
-
Kempen, Германия, 47906
- Novartis Investigative Site
-
Lübeck, Германия, 23538
- Novartis Investigative Site
-
Magdeburg, Германия, 39120
- Novartis Investigative Site
-
Magdeburg, Германия, 39104
- Novartis Investigative Site
-
Mainz, Германия, 55116
- Novartis Investigative Site
-
Marburg, Германия, 35043
- Novartis Investigative Site
-
Minden, Германия, 32429
- Novartis Investigative Site
-
Mönchengladbach, Германия, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Германия, 21629
- Novartis Investigative Site
-
Nuremberg, Германия, 90419
- Novartis Investigative Site
-
Oberasbach, Германия, 90522
- Novartis Investigative Site
-
Oelde, Германия, 59302
- Novartis Investigative Site
-
Peitz, Германия, 03185
- Novartis Investigative Site
-
Potsdam, Германия, 14469
- Novartis Investigative Site
-
Remscheid, Германия, 42897
- Novartis Investigative Site
-
Selters, Германия, 56242
- Novartis Investigative Site
-
Simmern, Германия, 55469
- Novartis Investigative Site
-
Soest, Германия, 59494
- Novartis Investigative Site
-
Stolberg, Германия, 52222
- Novartis Investigative Site
-
Unna, Германия, 59423
- Novartis Investigative Site
-
Wittlich, Германия, 54316
- Novartis Investigative Site
-
Wuppertal, Германия, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Германия, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Германия, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Германия, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Германия, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Германия, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Германия, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Германия, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Германия, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Германия, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Германия, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Германия, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Германия, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Германия, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Германия, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Германия, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Германия, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Германия, 06886
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Описание
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Proportion of patients receiving up-titration
Временное ограничение: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Временное ограничение: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Временное ограничение: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Временное ограничение: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Временное ограничение: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Временное ограничение: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Временное ограничение: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Временное ограничение: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Временное ограничение: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Временное ограничение: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Временное ограничение: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Временное ограничение: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CAIN457MDE01
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .